Cannabidiol as an Adjunct for the Treatment of Anorexia Nervosa (CAFTAN): An Open Label Pilot Trial with extension in Young People
About this study
Research Team
Prof. Iain McGregor, Prof Sarah Maguire, Sarah-Catherine Rodan, Dr. Karen Spielman, Prof. Janice Russell
Institution
The University of Sydney
Website
Funding Source
Lambert Initiative for Cannabinoid Therapeutics and InsideOut Institute for Eating Disorders
Project Start Date
1 April 2023
Project End Date
30 October 2024
Participants
Young persons aged between 12-18 years with anorexia nervosa
What is Involved
Participants will take CBD daily for three months during phase 1 re-feeding stage of treatment. The study medication will be provided monthly, delivered free of charge. CBD is non-intoxicating. Participants will not experience any psychoactive effects commonly associated with cannabis use.
Participants will be required to attend Maudsley Family Based Treatment sessions in the community with their therapist.
Patients will require a referral from their treating medical practitioner, confirming they are medically stable and will medically monitor the patient for the duration of the study.
Ethics Approval Number
X21-0440
Location
New South Wales Community, Australia
Contact Details
caftan.study@sydney.edu.au
We are recruiting young individuals aged 12-18 years with anorexia nervosa who are about to initiate or prepared to commence Maudsley Family Based Treatment for the first time. This study aims to investigate whether the addition of cannabidiol (CBD) to Maudsley Family Based Treatment can alleviate anxiety in young persons with anorexia nervosa to enhance treatment outcomes.
« Back to Browse Resources